Last Updated on May 31, 2020 by The Health Master
Swiss drugmaker Roche said that the US Food and Drug Administration (FDA) approved its immunotherapy Tecentriq in combination with its drug Avastin for the most common kind of liver cancer.
The Tecentriq-Avastin mix for unresectable or metastatic hepatocellular carcinoma was approved under the FDA’s Real-Time Oncology Review pilot and Project Orbis initiative aimed at speedier access for patients, Roche said.
Also read: Raw material shortage hinders HCQ production
The American Cancer Society estimated that more than 42,000 Americans will be diagnosed with liver cancer this year.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
